ORX.ST
Orexo AB (publ) [ORX.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ORX.ST Stock Summary
Top 10 Correlated ETFs
ORX.ST
Top 10 Correlated Stocks
ORX.ST
In the News
ORX.ST Financial details
Company Rating
Neutral
Market Cap
564.28M
Income
-128.4M
Revenue
638.6M
Book val./share
1.71
Cash/share
4.96
Dividend
-
Dividend %
-
Employees
116
Optionable
No
Shortable
Yes
Earnings
25 Apr 2024
P/E
-2.68
Forward P/E
-
PEG
0.97
P/S
0.86
P/B
5.87
P/C
3.47
P/FCF
-3.07
Quick Ratio
0.59
Current Ratio
1.67
Debt / Equity
7.97
LT Debt / Equity
7.61
-
-
EPS (TTM)
-3.74
EPS next Y
-
EPS next Q
-
EPS this Y
-27.85%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-5.44%
Revenue Q/Q
6.34%
EPS Q/Q
-44.33%
-
-
-
-
SMA20
13.33%
SMA50
13.33%
SMA100
13.33%
Inst Own
-
Inst Trans
-
ROA
-23%
ROE
-150%
ROC
-0.36%
Gross Margin
85%
Oper. Margin
-32%
Profit Margin
-32%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
8.44-20.1
52W High
-14%
52W Low
+115%
RSI
66
Rel Volume
0.28
Avg Volume
22.08K
Volume
6.11K
Perf Week
4.37%
Perf Month
3.61%
Perf Quarter
26.28%
Perf Half Y
8.18%
-
-
-
-
Beta
0.576
-
-
Volatility
0.47%, 0.83%
Prev Close
-1.71%
Price
17.2
Change
1.65%
ORX.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 24.4 | 19.29 | 16.46 | 18.17 | 18.56 | |
| Net income per share | 6.33 | -2.45 | -6.51 | -5.17 | -3.73 | |
| Operating cash flow per share | 8.29 | 0.49 | -6.67 | -4.56 | -2.76 | |
| Free cash flow per share | 7.37 | -5.03 | -8.21 | -5.25 | -3.31 | |
| Cash per share | 23.59 | 14.69 | 14.69 | 10.24 | 4.97 | |
| Book value per share | 20.4 | 16.24 | 10.19 | 5.64 | 1.71 | |
| Tangible book value per share | 17.11 | 9.42 | 2.94 | -0.68 | -3.32 | |
| Share holders equity per share | 20.4 | 16.24 | 10.19 | 5.64 | 1.71 | |
| Interest debt per share | 10.51 | 8.93 | 16.86 | 16.52 | 14.83 | |
| Market cap | 2.17B | 1.72B | 1.18B | 647.87M | 549.93M | |
| Enterprise value | 1.7B | 1.51B | 1.23B | 1.06B | 852.73M | |
| P/E ratio | 9.92 | -20.38 | -5.3 | -3.65 | -4.29 | |
| Price to sales ratio | 2.57 | 2.59 | 2.1 | 1.04 | 0.86 | |
| POCF ratio | 7.58 | 102.38 | -5.17 | -4.14 | -5.79 | |
| PFCF ratio | 8.53 | -9.95 | -4.2 | -3.59 | -4.83 | |
| P/B Ratio | 3.08 | 3.08 | 3.39 | 3.34 | 9.34 | |
| PTB ratio | 3.08 | 3.08 | 3.39 | 3.34 | 9.34 | |
| EV to sales | 2.01 | 2.27 | 2.18 | 1.69 | 1.33 | |
| Enterprise value over EBITDA | 5.9 | 89.62 | -8.71 | -14.24 | -18.7 | |
| EV to operating cash flow | 5.93 | 89.62 | -5.37 | -6.74 | -8.98 | |
| EV to free cash flow | 6.67 | -8.71 | -4.37 | -5.85 | -7.49 | |
| Earnings yield | 0.1 | -0.05 | -0.19 | -0.27 | -0.23 | |
| Free cash flow yield | 0.12 | -0.1 | -0.24 | -0.28 | -0.21 | |
| Debt to equity | 0.49 | 0.52 | 1.57 | 2.78 | 7.97 | |
| Debt to assets | 0.23 | 0.24 | 0.43 | 0.49 | 0.6 | |
| Net debt to EBITDA | -1.64 | -12.76 | -0.33 | -5.5 | -6.64 | |
| Current ratio | 2.65 | 1.38 | 2.28 | 1.91 | 1.74 | |
| Interest coverage | 11.86 | -1.36 | -7.98 | -7.71 | -2.98 | |
| Income quality | 1.24 | -0.84 | 1.07 | 0.85 | 0.74 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.17 | 0.15 | 0.27 | 0.32 | 0.29 | |
| Research and developement to revenue | 0.21 | 0.34 | 0.48 | 0.51 | 0.37 | |
| Intangibles to total assets | 0.08 | 0.19 | 0.2 | 0.2 | 0.22 | |
| Capex to operating cash flow | -0.11 | -11.29 | 0.23 | 0.15 | 0.2 | |
| Capex to revenue | -0.04 | -0.29 | -0.09 | -0.04 | -0.03 | |
| Capex to depreciation | -0.78 | -4.88 | -1 | -0.35 | -0.25 | |
| Stock based compensation to revenue | 0.01 | -0.03 | 0 | 0 | 0 | |
| Graham number | 53.9 | 29.94 | 38.63 | 25.62 | 11.98 | |
| ROIC | 0.2 | -0.05 | -0.24 | -0.29 | -0.21 | |
| Return on tangible assets | 0.16 | -0.08 | -0.22 | -0.2 | -0.21 | |
| Graham Net | 8.44 | 1.41 | -5.01 | -8.57 | -10.93 | |
| Working capital | 760.2M | 230.3M | 485.3M | 349.6M | 195.7M | |
| Tangible asset value | 592.4M | 324.2M | 100.8M | -23.5M | -114.3M | |
| Net current asset value | 426.5M | 157.2M | -58.6M | -179.6M | -268.8M | |
| Invested capital | 0.49 | 0.52 | 1.57 | 2.78 | 7.97 | |
| Average receivables | 136.25M | 245.15M | 243.5M | 289.1M | 260.85M | |
| Average payables | 48.55M | 48.2M | 48.1M | 67.9M | 61.55M | |
| Average inventory | 152.7M | 120.1M | 100.35M | 83.45M | 58.5M | |
| Days sales outstanding | 117.73 | 119.8 | 173.91 | 180.66 | 121.53 | |
| Days payables outstanding | 170.75 | 261.51 | 227.6 | 308.08 | 80.26 | |
| Days of inventory on hand | 455.56 | 603.14 | 426.99 | 265.39 | 93.23 | |
| Receivables turnover | 3.1 | 3.05 | 2.1 | 2.02 | 3 | |
| Payables turnover | 2.14 | 1.4 | 1.6 | 1.18 | 4.55 | |
| Inventory turnover | 0.8 | 0.61 | 0.85 | 1.38 | 3.92 | |
| ROE | 0.31 | -0.15 | -0.64 | -0.92 | -2.18 | |
| Capex per share | -0.92 | -5.51 | -1.54 | -0.7 | -0.55 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 4.54 | 4.62 | 4.58 | 4.54 | 4.82 | |
| Net income per share | -2.67 | -1.86 | -0.37 | -0.97 | -0.54 | |
| Operating cash flow per share | -1.42 | -1.79 | -0.37 | -0.64 | -0.08 | |
| Free cash flow per share | -1.77 | -1.82 | -0.68 | -0.83 | -0.07 | |
| Cash per share | 10.24 | 8.12 | 7.3 | 5.35 | 4.96 | |
| Book value per share | 5.64 | 3.76 | 3.6 | 2.67 | 1.71 | |
| Tangible book value per share | -0.68 | -2.27 | -2.15 | -2.74 | -3.32 | |
| Share holders equity per share | 5.64 | 3.76 | 3.6 | 2.67 | 1.71 | |
| Interest debt per share | 17.62 | 15.7 | 15.11 | 14.14 | 13.94 | |
| Market cap | 648.17M | 525.14M | 357.92M | 557.61M | 550.5M | |
| Enterprise value | 1.06B | 913.14M | 623.92M | 852.11M | 853.3M | |
| P/E ratio | -1.77 | -2.05 | -7.1 | -4.19 | -7.4 | |
| Price to sales ratio | 4.15 | 3.31 | 2.27 | 3.57 | 3.32 | |
| POCF ratio | -13.28 | -8.52 | -28.18 | -25.46 | -211.73 | |
| PFCF ratio | -10.63 | -8.42 | -15.23 | -19.5 | -220.2 | |
| P/B Ratio | 3.34 | 4.07 | 2.89 | 6.06 | 9.35 | |
| PTB ratio | 3.34 | 4.07 | 2.89 | 6.06 | 9.35 | |
| EV to sales | 6.77 | 5.75 | 3.96 | 5.46 | 5.14 | |
| Enterprise value over EBITDA | -90.22 | -22.22 | 113.44 | -90.65 | 42.67 | |
| EV to operating cash flow | -21.63 | -14.82 | -49.13 | -38.91 | -328.19 | |
| EV to free cash flow | -17.3 | -14.63 | -26.55 | -29.79 | -341.32 | |
| Earnings yield | -0.14 | -0.12 | -0.04 | -0.06 | -0.03 | |
| Free cash flow yield | -0.09 | -0.12 | -0.07 | -0.05 | 0 | |
| Debt to equity | 2.78 | 4.11 | 4.18 | 5.2 | 7.97 | |
| Debt to assets | 0.49 | 0.56 | 0.56 | 0.55 | 0.6 | |
| Net debt to EBITDA | -34.82 | -9.44 | 48.36 | -31.33 | 15.14 | |
| Current ratio | 1.91 | 1.93 | 1.87 | 1.67 | 1.74 | |
| Interest coverage | -1.54 | -6.45 | -4.64 | -3.58 | -0.09 | |
| Income quality | 0.69 | 1.04 | 0.98 | 0.77 | 0.14 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.41 | 0.42 | 0.24 | 0.29 | 0.23 | |
| Research and developement to revenue | 0.57 | 0.49 | 0.48 | 0.54 | 0.39 | |
| Intangibles to total assets | 0.2 | 0.22 | 0.21 | 0.21 | 0.22 | |
| Capex to operating cash flow | 0.25 | 0.01 | 0.85 | 0.31 | -0.04 | |
| Capex to revenue | -0.08 | -0.01 | -0.07 | -0.04 | 0 | |
| Capex to depreciation | -0.68 | -0.04 | -0.58 | -0.35 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 18.41 | 12.54 | 5.44 | 7.63 | 4.56 | |
| ROIC | -0.13 | -0.08 | -0.02 | -0.04 | 0 | |
| Return on tangible assets | -0.1 | -0.09 | -0.02 | -0.05 | -0.03 | |
| Graham Net | -8.56 | -9.45 | -9.61 | -10.42 | -10.91 | |
| Working capital | 349.6M | 283.6M | 264.7M | 208.4M | 195.7M | |
| Tangible asset value | -23.5M | -78.1M | -74M | -94.4M | -114.3M | |
| Net current asset value | -179.6M | -230.9M | -234.4M | -258.9M | -268.8M | |
| Invested capital | 2.78 | 4.11 | 4.18 | 5.2 | 7.97 | |
| Average receivables | 302M | 277.35M | 248.1M | 259.9M | 241M | |
| Average payables | 139.8M | 121.35M | 147.05M | 147.5M | 96.75M | |
| Average inventory | 81.65M | 69.65M | 65.9M | 65.85M | 53.5M | |
| Days sales outstanding | 178.27 | 139.25 | 142.96 | 155.27 | 115.32 | |
| Days payables outstanding | 300.93 | 489.51 | 722.09 | 619.74 | 79.93 | |
| Days of inventory on hand | 259.23 | 202.89 | 351.1 | 255 | 92.85 | |
| Receivables turnover | 0.5 | 0.65 | 0.63 | 0.58 | 0.78 | |
| Payables turnover | 0.3 | 0.18 | 0.12 | 0.15 | 1.13 | |
| Inventory turnover | 0.35 | 0.44 | 0.26 | 0.35 | 0.97 | |
| ROE | -0.47 | -0.49 | -0.1 | -0.36 | -0.32 | |
| Capex per share | -0.35 | -0.02 | -0.31 | -0.19 | 0 |
ORX.ST Frequently Asked Questions
What is Orexo AB (publ) stock symbol ?
Orexo AB (publ) is a SE stock and trading under the symbol ORX.ST
What is Orexo AB (publ) stock quote today ?
Orexo AB (publ) stock price is $17.2 today.
Is Orexo AB (publ) stock public?
Yes, Orexo AB (publ) is a publicly traded company.
Company Profile
- Volume Average 22.08K
- Market Capitalization 564.28M
- Employee 116
- CEO Mr. Nikolaj Sorensen
- Headquarters Uppsala,SE
- IPO Date 2005-11-09
-
Website
https://www.orexo.com 
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
